RxDoctor Payments Data

Moonyoung Chung, MD

Ophthalmology · Saginaw, MINPI 1689685463

Payments from drug & device makers

$1,289in general payments, 2019–2025

Across 96 payments — averaging $13.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$321
  • Bausch & Lomb Americas Inc.$259
  • Alcon$143
  • Astellas Pharma US Inc$132
  • AbbVie$103
  • Sun Pharmaceutical Industries Inc.$86
  • plus $244 from 8 others

What the payments were for

  • Food & beverage$1,289100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,289 in reported general payments places this provider in the 50th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$106,705
Medicare patients
646
Services billed
1,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine161$175,354
XiidraLifitegrast130$135,939
LumiganBimatoprost140$80,364
Cyclosporine115$53,051
VyzultaLatanoprostene Bunod39$26,059
Brimonidine Tartrate247$22,939
Prednisolone Acetate402$18,040
Restasis MultidoseCyclosporine27$18,022
CombiganBrimonidine Tartrate/Timolol30$14,078
SimbrinzaBrinzolamide/Brimonidine Tart38$11,058
ErythromycinErythromycin Base637$8,187
Latanoprost507$8,118
Bimatoprost54$7,004
RocklatanNetarsudil Mesylat/Latanoprost20$6,876
Timolol Maleate100$6,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose, Combigan$103$287,818358 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$259$161,999169 claims
AlconSimbrinza$143$11,05838 claims
Aerie Pharmaceuticals, Inc.Rocklatan$47$6,87620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →